-
EP2943193
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2943193
| EP2943193 - CANCER DRUG COMPOSITION COMPRISING METFORMIN, ATORVASTATIN AND MEBENDAZOLE AND USES THEREOF [Right-click to bookmark this link] | |||
| Former [2015/47] | CANCER DRUG AND USES | ||
| [2023/33] | Status | The application is deemed to be withdrawn Status updated on 10.05.2024 Database last updated on 09.09.2024 | |
| Former | Grant of patent is intended Status updated on 05.09.2023 | ||
| Former | Examination is in progress Status updated on 14.04.2017 | Most recent event Tooltip | 10.05.2024 | Application deemed to be withdrawn | published on 12.06.2024 [2024/24] | Applicant(s) | For all designated states Clinics Operations Limited The Walbrook Building 25 Walbrook London EC4N 8AF / GB | [2022/10] |
| Former [2015/47] | For all designated states Health Clinics Limited 100 Fetter Lane London EC4A 1BN / GB | Inventor(s) | 01 /
BANNISTER, Robin Mark Biocopea Limited Centralpoint 45 Beech Street London Greater London EC2Y 8AD / GB | 02 /
BREW, John Biocopoea Limited Centralpoint 45 Beech Street London Greater London EC2Y 8AD / GB | 03 /
STOLOFF, Gregory Alan Biocopea Limited Centralpoint 45 Beech Street London Greater London EC2Y 8AD / GB | [2015/47] | Representative(s) | Clements, Andrew Russell Niel Schlich 9 St Catherine's Road Littlehampton, West Sussex BN17 5HS / GB | [2015/47] | Application number, filing date | 14702201.6 | 14.01.2014 | [2015/47] | WO2014EP50635 | Priority number, date | US201361752360P | 14.01.2013 Original published format: US 201361752360 P | US201361782585P | 14.03.2013 Original published format: US 201361782585 P | US201361872822P | 02.09.2013 Original published format: US 201361872822 P | [2015/47] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2014108571 | Date: | 17.07.2014 | Language: | EN | [2014/29] | Type: | A2 Application without search report | No.: | EP2943193 | Date: | 18.11.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.07.2014 takes the place of the publication of the European patent application. | [2015/47] | Search report(s) | International search report - published on: | EP | 04.09.2014 | (Supplementary) European search report - dispatched on: | EP | 13.04.2017 | Classification | IPC: | A61K31/155, A61K31/4184, A61K31/40, A61P35/00 | [2023/33] | CPC: |
A61K31/59 (EP,US);
A23L33/10 (EP,US);
A61K31/05 (EP,US);
A61K31/155 (EP,US);
A61K31/19 (EP,US);
A61K31/225 (EP,US);
A61K31/352 (EP,US);
A61K31/353 (EP,US);
A61K31/357 (EP,US);
A61K31/366 (EP,US);
A61K31/375 (EP,US);
A61K31/40 (EP,US);
A61K31/4184 (EP,US);
A61K31/517 (EP,US);
A61K31/7068 (EP,US);
A61K39/39558 (US);
A61K9/48 (US);
A61K9/4858 (US);
| C-Set: |
A61K31/05, A61K2300/00 (EP,US);
A61K31/105, A61K2300/00 (EP,US);
A61K31/155, A61K2300/00 (EP,US);
A61K31/352, A61K2300/00 (EP,US);
A61K31/357, A61K2300/00 (US,EP);
A61K31/366, A61K2300/00 (US,EP);
A61K31/4184, A61K2300/00 (EP,US);
A61K31/517, A61K2300/00 (US,EP); |
| Former IPC [2015/47] | A61K31/357, A61K31/517, A61K31/7068, A61K31/05, A61K31/155, A61K31/352, A61K31/366, A61K31/4184, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/47] | Title | German: | KREBSHEILMITTEL ENTHALTEND METFORMIN, ATORVASTATIN UND MEBENDAZOL UND VERWENDUNGEN DAVON | [2023/33] | English: | CANCER DRUG COMPOSITION COMPRISING METFORMIN, ATORVASTATIN AND MEBENDAZOLE AND USES THEREOF | [2023/33] | French: | MÉDICAMENT CONTRE LE CANCER COMPRENANT DE LA METFORMINE, DE L'ATORVASTATINE ET DE LA MÉBENDAZOLE ET LEURS UTILISATIONS | [2023/33] |
| Former [2015/47] | KREBSHEILMITTEL UND VERWENDUNGEN DAVON | ||
| Former [2015/47] | CANCER DRUG AND USES | ||
| Former [2015/47] | MÉDICAMENT CONTRE LE CANCER ET UTILISATIONS | Entry into regional phase | 13.08.2015 | National basic fee paid | 13.08.2015 | Designation fee(s) paid | 13.08.2015 | Examination fee paid | Examination procedure | 13.08.2015 | Examination requested [2015/47] | 22.02.2016 | Amendment by applicant (claims and/or description) | 13.04.2017 | Despatch of a communication from the examining division to which search results under Rule 164(2) EPC are annexed (Time limit: M06) [2017/20] | 13.04.2017 | Despatch of a communication from the examining division (Time limit: M06) | 23.10.2017 | Reply to a communication from the examining division | 25.07.2018 | Despatch of a communication from the examining division (Time limit: M06) | 24.01.2019 | Reply to a communication from the examining division | 16.09.2019 | Despatch of a communication from the examining division (Time limit: M06) | 19.03.2020 | Reply to a communication from the examining division | 18.06.2020 | Despatch of a communication from the examining division (Time limit: M04) | 26.06.2020 | Reply to a communication from the examining division | 16.11.2020 | Despatch of a communication from the examining division (Time limit: M06) | 13.04.2021 | Reply to a communication from the examining division | 08.04.2022 | Cancellation of oral proceeding that was planned for 10.05.2022 | 10.05.2022 | Date of oral proceedings (cancelled) | 06.09.2023 | Communication of intention to grant the patent | 17.01.2024 | Application deemed to be withdrawn, date of legal effect [2024/24] | 06.02.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2024/24] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 13.04.2017 | Fees paid | Renewal fee | 29.01.2016 | Renewal fee patent year 03 | 24.01.2017 | Renewal fee patent year 04 | 29.01.2018 | Renewal fee patent year 05 | 28.01.2019 | Renewal fee patent year 06 | 26.11.2019 | Renewal fee patent year 07 | 13.01.2021 | Renewal fee patent year 08 | 16.12.2021 | Renewal fee patent year 09 | 07.07.2023 | Renewal fee patent year 10 | Penalty fee | Additional fee for renewal fee | 31.01.2023 | 10 M06 Fee paid on 07.07.2023 | 31.01.2024 | 11 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XY]WO0027359 (PILKIEWICZ FRANK G [US]) [X] 1-3,19-31,35,36,39 * claims 1,23-26 * [Y] 37,38; | [XY]CN1435167 (UNIV TSINGHUA [CN]) [X] 1-3,19-31,35,36,39 * abstract * * examples 1-3; claims 1,2 * [Y] 37,38; | [X] - LEE C W ET AL, "Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 64, no. 3, doi:10.1016/J.LUNGCAN.2008.09.008, ISSN 0169-5002, (20090601), pages 308 - 313, (20081111), XP026089673 [X] 27-29 * table 1 * DOI: http://dx.doi.org/10.1016/j.lungcan.2008.09.008 | by applicant | US4756911 | US5378475 | US2005181017 | US2005244464 | US7048946 | US2011008437 |